{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Surgical+Standard+of+Care",
    "query": {
      "intervention": "Surgical Standard of Care"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 2845,
    "total_pages": 285,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Surgical+Standard+of+Care&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T12:19:58.252Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02070640",
      "title": "Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cholecystitis"
      ],
      "interventions": [
        {
          "name": "Injection of indocyanine green (ICG)",
          "type": "DRUG"
        },
        {
          "name": "Near Infrared Cholangiography Fluorescence (NIRF-C)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 99,
      "start_date": "2013-01",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2015-10-21",
      "last_synced_at": "2026-09-24T12:19:58.252Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02070640"
    },
    {
      "nct_id": "NCT04033510",
      "title": "Acute Cognitive Changes During Atrial Fibrillation Episodes (AFCOG)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atrial Fibrillation",
        "Cognitive Symptom",
        "Executive Dysfunction",
        "Cognitive Change",
        "Cognitive Impairment",
        "Cognitive Impairment, Mild"
      ],
      "interventions": [
        {
          "name": "Standard of Care Interventions to convert patient from atrial fibrillation to normal rhythm",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "David Brunk, PA-C, MMS",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "35 Years to 80 Years"
      },
      "enrollment_count": 600,
      "start_date": "2019-08-14",
      "completion_date": "2027-01-30",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-09-24T12:19:58.252Z",
      "location_count": 1,
      "location_summary": "Colorado Springs, Colorado",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04033510"
    },
    {
      "nct_id": "NCT06636669",
      "title": "Probiotics in the Prevention of Recurrent Prosthetic Joint Infection of the Hip and Knee",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Prosthetic-joint Infection",
        "Dysbiosis"
      ],
      "interventions": [
        {
          "name": "Probiotic",
          "type": "DRUG"
        },
        {
          "name": "Standard of care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Boston Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 152,
      "start_date": "2025-08-15",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-09-24T12:19:58.252Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06636669"
    },
    {
      "nct_id": "NCT04437069",
      "title": "Improving Patient and Family Health Using Family-Centered Outcomes and Shared Decision-Making",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Patient Decision Aids",
        "Congenital Heart Disease",
        "Congenital Heart Defect"
      ],
      "interventions": [
        {
          "name": "Decision Aid",
          "type": "OTHER"
        },
        {
          "name": "Values Clarification Exercise",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2020-10-01",
      "completion_date": "2026-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-09-24T12:19:58.252Z",
      "location_count": 2,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04437069"
    },
    {
      "nct_id": "NCT03929562",
      "title": "Alcohol Screening and Pre-Operative Intervention Research Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alcohol Drinking"
      ],
      "interventions": [
        {
          "name": "Brief advice",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Health coaching",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 65,
      "start_date": "2019-08-20",
      "completion_date": "2021-08-17",
      "has_results": true,
      "last_update_posted_date": "2022-11-15",
      "last_synced_at": "2026-09-24T12:19:58.252Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03929562"
    },
    {
      "nct_id": "NCT05196191",
      "title": "Wound Healing Following Penile Prosthesis Implant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Erectile Dysfunction"
      ],
      "interventions": [
        {
          "name": "VIAGENEX Max",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hibiclens wash",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "VIVEX Biologics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "30 Years to 70 Years · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2022-01-03",
      "completion_date": "2023-12-30",
      "has_results": false,
      "last_update_posted_date": "2024-03-01",
      "last_synced_at": "2026-09-24T12:19:58.252Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05196191"
    },
    {
      "nct_id": "NCT01042379",
      "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Breast Cancer",
        "Breast Tumors",
        "Angiosarcoma",
        "TNBC - Triple-Negative Breast Cancer",
        "HER2-positive Breast Cancer",
        "HER2-negative Breast Cancer",
        "Hormone Receptor Positive Tumor",
        "Hormone Receptor Negative Tumor",
        "Early-stage Breast Cancer",
        "Locally Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Standard Therapy",
          "type": "DRUG"
        },
        {
          "name": "AMG 386 with or without Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "AMG 479 (Ganitumab) plus Metformin",
          "type": "DRUG"
        },
        {
          "name": "MK-2206 with or without Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "AMG 386 and Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "T-DM1 and Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab and Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Ganetespib",
          "type": "DRUG"
        },
        {
          "name": "ABT-888",
          "type": "DRUG"
        },
        {
          "name": "Neratinib",
          "type": "DRUG"
        },
        {
          "name": "PLX3397",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab - 4 cycle",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib plus Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Patritumab and Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab - 8 cycle",
          "type": "DRUG"
        },
        {
          "name": "SGN-LIV1A",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab plus Olaparib",
          "type": "DRUG"
        },
        {
          "name": "SD-101 + Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Tucatinib plus trastuzumab and pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab plus REGN3767",
          "type": "DRUG"
        },
        {
          "name": "Trilaciclib with or without trastuzumab + pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "SYD985 ([vic-]trastuzumab duocarmazine)",
          "type": "DRUG"
        },
        {
          "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Amcenestrant",
          "type": "DRUG"
        },
        {
          "name": "Amcenestrant + Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Amcenestrant + Letrozole",
          "type": "DRUG"
        },
        {
          "name": "ARX788",
          "type": "DRUG"
        },
        {
          "name": "ARX788 + Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "VV1 + Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Datopotamab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Datopotamab deruxtecan + Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Zanidatamab",
          "type": "DRUG"
        },
        {
          "name": "Lasofoxifene",
          "type": "DRUG"
        },
        {
          "name": "Z-endoxifen",
          "type": "DRUG"
        },
        {
          "name": "ARV-471",
          "type": "DRUG"
        },
        {
          "name": "ARV-471 + Letrozole",
          "type": "DRUG"
        },
        {
          "name": "ARV-471 + Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Endoxifen + Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Rilvegostomig + TDXd",
          "type": "DRUG"
        },
        {
          "name": "Dan222 + Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Sarilumab + Cemiplimab + Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "GSK 5733584",
          "type": "DRUG"
        },
        {
          "name": "GSK 5733584 + Dostarlimab",
          "type": "DRUG"
        },
        {
          "name": "Ivonescimab (20mg/kg Q3W)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QuantumLeap Healthcare Collaborative",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5000,
      "start_date": "2010-03-01",
      "completion_date": "2031-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-09-24T12:19:58.252Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01042379"
    },
    {
      "nct_id": "NCT00494494",
      "title": "Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cystoid Macular Edema"
      ],
      "interventions": [
        {
          "name": "Standard Care",
          "type": "DRUG"
        },
        {
          "name": "nepafenac",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2007-06",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2011-07-12",
      "last_synced_at": "2026-09-24T12:19:58.252Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00494494"
    },
    {
      "nct_id": "NCT04301661",
      "title": "Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "Blood collection",
          "type": "OTHER"
        },
        {
          "name": "Abacavir/lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir alafenamide/emtricitabine",
          "type": "DRUG"
        },
        {
          "name": "Switch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 25,
      "start_date": "2020-03-06",
      "completion_date": "2021-12-17",
      "has_results": false,
      "last_update_posted_date": "2023-01-09",
      "last_synced_at": "2026-09-24T12:19:58.252Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04301661"
    },
    {
      "nct_id": "NCT01472627",
      "title": "Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Blood draws",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2010-10",
      "completion_date": "2018-01",
      "has_results": false,
      "last_update_posted_date": "2018-01-11",
      "last_synced_at": "2026-09-24T12:19:58.252Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01472627"
    }
  ]
}